ClinicalTrials.gg
CompletedNCT03433196HS-25-III-02Updated Oct 18, 2018

Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases

A Phase 3 interventional study of HS-25 and Atorvastatin and Atorvastatin in Hypercholesterolemia in Coronaory Heart Disease, sponsored by Zhejiang Hisun Pharmaceutical Co. Ltd.. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jun 2016, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
32nd of 75
255 · median 148
Started
2016
the only one that year
Phase 3
31 of 77
none open now
Registered
69th of 77
by date

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 32nd largest by enrollment of the 75 interventional ones that give a count, is the only one that started in 2016, is one of 31 in phase 3, and was the 69th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases; To determine the safety of HS-25 (20mg) combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases

03

Conditions studied

  • Hypercholesterolemia in Coronaory Heart Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diet control for 14 weeks, Atorvastatin 10mg once daily for 6 weeks or above;
  • The average of both qualifying values must be in the range of 2.07 mmol/L to 3.36 mmol/L. Run-in (Visit 2 and Visit 3) and the Visit 3 value must be within 12% of the value at Visit 2, higher or lower;
  • Must meet the one of diseases as following:

    1. Subjects who have stable coronary heart disease;
    2. Subjects who diagnosed ischemic stroke in stable condition;
    3. Subjects who diagnosed as Diabetes mellitus

Exclusion criteria

Exclusion Criteria:

  • history of Severe Endiocrine disease (for example Thyroid function abnormal);
  • History of advanced cancer
  • Arrhythmias need to be treated by medications history of Hemorrhagic stroke;
  • Cardiac dysfunction;
  • Unstable ASCVD;
  • History of organ transplant;
  • Hypersensitive to HS-25 or place;
  • uncontrolled or new diagnosed diabetes mellitus;
  • and positive
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    HS-25 and Atorvastatin

    HS-25 20mg, Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet

    Drug: HS-25 and Atorvastatin

  • Active comparator
    Atorvastatin

    Atorvastatin 20mg, Placebo of HS-25 2 tablets

    Drug: Atorvastatin

Interventions

  • DrugHS-25 and Atorvastatin

    Drug pages: HS-25 · Atorvastatin

    HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily

  • Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily

06

What researchers measure

Primary outcomes

  1. Percent change of LDL-C

    Percent change from baseline in LDL-C after 2,4,8,12 weeks of double-blind treatment

    Time frame: 2,4,8,12 weeks

Secondary outcomes

  1. Percent change of Non-HDL-C

    Percent change from baseline in Non-HDL-C after 2,4,8,12 weeks of double-blind treatment

    Time frame: 2,4,8,12 weeks

  2. Percent change of TC,TG,ApoB,ApoAI

    Percent change from baseline in TC,TG,ApoB and ApoAI after 2,4,8,12 weeks of double-blind treat

    Time frame: 2,4,8,12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Jun 2018, 24 months.

Of 123 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 126 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2018
First posted
Feb 14, 2018
StartActual
Jun 7, 2016
Primary completionActual
Jun 30, 2018
CompletionActual
Oct 10, 2018
Last update
Oct 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03433196
Lead sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd.
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Jun 7, 2016
Primary completion
Jun 30, 2018
Completion
Oct 10, 2018
Last update
Oct 18, 2018

Study contacts

Litong Qi
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HS-25 · Atorvastatin

Start the discussion